In Brief: Anika Research
This article was originally published in The Gray Sheet
Executive Summary
Anika Research: Files CE mark registration for European marketing approval of its Orthovisc "ultra-pure" high molecular weight hyaluronic acid product, which is "used to relieve pain, reduce inflammation and improve joint function in patients with osteoarthritis," the firm states. Anika recently initiated a Phase III double-blind, placebo-controlled trial of the product in the U.S. for treating osteoarthritis of the knee. The study is expected to include 220 patients...